COGT at a glance
Cogent Biosciences, Inc. (COGT, SEC CIK 1622229) filed its latest 10-K annual report on February 17, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on September 2, 2026 and Form 4 insider filings as recently as October 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 33 institutional investment managers tracked by SignalX reported holding Cogent Biosciences, Inc. (COGT) shares worth $3.3 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Morris Arlene on August 27, 2026 of 3,161 shares at $37.54 per share.
- In the last 90 days, COGT insiders reported 0 open-market purchases ($0) and 2 open-market sales ($1.7M) on Form 4, a net sale of $1.7M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 2 sells
- Net −$1.7M
- 13F holders
- 33 funds
- $3.3B · +3 vs prior quarter
- Latest 8-K
- Sep 2, 2026
- Item 1.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Clinical-stage biotech developing precision therapies targeting genetically defined diseases, focusing mainly on tyrosine kinase inhibitors like bezuclastinib
- New emphasis: Positive top-line Phase 2/3 results in 2025 for bezuclastinib in Non-Advanced/Advanced Systemic Mastocytosis and GIST; expecting U.S. launches in H2 2026
- Strategic shift: Building internal U.S. commercial organization for bezuclastinib launch, alongside advancing Phase 1 studies for FGFR2/3 and mutant ErbB2 inhibitors, and progressing PI3Kα, KRAS, JAK2 preclinicals
- Quantitative highlight: PEAK trial median PFS 16.5 months with bezuclastinib plus sunitinib vs. 9.2 months sunitinib alone; 50% risk reduction in progression or death
- Noteworthy: FDA granted Breakthrough Therapy Designations for bezuclastinib in multiple indications and accepted NDAs under expedited review programs in 2025-2026
Risk Factors
- Regulatory risk: FDA NDA submissions for bezuclastinib in NonAdvSM (2025) and GIST (expected April 2026) may face approval delays or rejections
- Macroeconomic threat: U.S. healthcare pricing pressure from May 2025 White House Most Favored Nation drug pricing policy impacting reimbursement
- Supply chain vulnerability: Dependence on CMOs for clinical trial materials; CMO failure could delay trials and force costly in-house manufacturing
- Competitive risk: Competition from larger pharma and biotech firms with greater resources and faster FDA approvals for precision medicines targeting same diseases
- Financial risk: Need for substantial investment in commercial manufacturing capacity and marketing before generating bezuclastinib revenue
Management Discussion & Analysis
- Net loss $328.9M in 2025 vs $255.9M in 2024, increase of $73M; no product revenue generated
- R&D expense $269.8M in 2025 vs $232.7M in 2024, up $37.1M; G&A $63.6M vs $43.3M, up $20.3M
- Bezuclastinib trials expenses flat at ~$120M; early-stage programs +$12M; personnel costs +$21.1M including $4.1M stock comp
- Cash, cash equivalents, and marketable securities $900.8M as of Dec 31, 2025, sufficient to fund operations into 2028
- Management expects increased expenses for regulatory approvals, commercial launch, manufacturing, and pipeline expansion
AI summary of the COGT 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $0; no product sales, unchanged from prior-year quarter
- Net loss $96.4M vs $73.5M YoY; operating loss $102.6M vs $75.6M
- Best R&D line bezuclastinib $25.6M; lowest early-stage programs $11.8M
- Cash, equivalents and marketable securities $792.3M; $71.4M post-quarter ATM proceeds
- Funding expected into late 2028; U.S. launch anticipated second half 2026 pending approval
Risk Factors
- No material risk-factor changes from December 31, 2025 Form 10-K
- Clinical-stage biotechnology risk remains significant, with additional unknown or immaterial risks potentially affecting results
- No newly triggered regulatory, legal, or compliance risk identified this quarter
- No specific liquidity, debt-maturity, currency, or concentration risk updated in the filing
AI summary of the COGT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 1.01: Entry into a Material Definitive Agreement
- Five-year supply agreement with Hovione for bezuclastinib spray-dried dispersion and tablets
- Minimum purchase percentages decline over the contract term, creating initial supplier concentration and volume commitments
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release dated August 10, 2026 contains the substantive operating and financial details
Item EX-99.1: Item EX-99.1
- Q2 2026 loss $96.4M versus $73.5M; operating expenses rose to $102.6M amid clinical and commercial launch investment
- Cash $792.3M plus $73.6M ATM proceeds, supporting operations into late 2028 through potential approvals and early launch activities
Item 8.01: Other Events
- $400M at-the-market equity offering capacity added through Guggenheim Securities
- Common shares may be sold periodically at prevailing market prices
AI summaries of COGT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for COGT
Don't miss the next COGT filing
- Alerts as it files. A push when COGT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut COGT, by share count.
- Ask anything. An AI agent that reads every COGT filing and answers with sources.
COGT alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Ferrante Karen Jean | A | Oct 1, 2026 | 759 | - |
| Morris Arlene | Sell | Aug 27, 2026 | 3,161 | $37.54 |
| Morris Arlene | Sell | Aug 27, 2026 | 42,349 | $37.09 |
| Morris Arlene | M | Aug 27, 2026 | 41,927 | - |
| Morris Arlene | M | Aug 27, 2026 | 3,583 | - |
| Morris Arlene | M | Aug 27, 2026 | 3,583 | $2.52 |
| Morris Arlene | M | Aug 27, 2026 | 41,927 | $5.64 |
| Ferrante Karen Jean | A | Jul 1, 2026 | 627 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$208.1M | -$275.9M | -$333.4M |
| Net Income | -$192.4M | -$255.9M | -$328.9M |
| Balance Sheet | |||
| Total Assets | $313.4M | $327.9M | $937.6M |
| Equity | $257.8M | $256.3M | $636.4M |
| ROE | -74.6% | -99.8% | -51.7% |
| Per Share | |||
| EPS | - | $-1.94 | $-2.16 |
| Cash Flow | |||
| Operating CF | -$153.6M | -$207.8M | -$264.4M |
| CapEx | $2.8M | $573K | $1.6M |
Source: XBRL data in Cogent Biosciences, Inc. (COGT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate COGT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 33 | $3.32B |
| Q1 2026 | 30 | $3.06B |
| Q4 2025 | 26 | $2.42B |
| Q3 2025 | 23 | $825.9M |
| Q2 2025 | 23 | $313.8M |
| Q1 2025 | 22 | $213.5M |
| Q4 2024 | 17 | $241.6M |
| Q3 2024 | 14 | $97.0M |
- FMR LLC (Fidelity)+2.56M (+11%)
- T. Rowe Price Group+1.44M (+45%)
- BlackRock+1.31M (+8%)
- State Street Corp+1.30M (+23%)
- Vanguard Portfolio Management LLC+739.1K (+10%)
- Goldman Sachs Group−2.15M (-48%)
- D.E. Shaw & Co−945.9K (-51%)
- Citadel Advisors LLC−865.2K (-50%)
- Millennium Management−284.7K (-24%)
- Prudential Financial−34.7K (-19%)
- Blackstone Group+9.4K
- Allstate+6.5K
- Marex Group plc+6.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 188 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
COGT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 5, 2026 | - | - | - |
| 8-K | Sep 2, 2026 | - | Analysis | - |
| 4 | Aug 31, 2026 | - | - | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| SC 13G | Jul 31, 2026 | - | - | |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 8-K | Jun 11, 2026 | - | Analysis | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | May 21, 2026 | - | - | |
| 8-K | May 5, 2026 | - | Analysis | - |
| 10-Q | May 5, 2026 | Mar 31, 2026 | Analysis | |
| 4 | Apr 3, 2026 | - | - | - |
| 4 | Mar 31, 2026 | - | - | - |
| 8-K | Feb 17, 2026 | - | - | |
| 10-K | Feb 17, 2026 | Dec 31, 2025 | Analysis | |
| 4 | Jan 22, 2026 | - | - | |
| 4 | Jan 5, 2026 | - | - | |
| 4 | Dec 30, 2025 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
COGT SEC filings: frequently asked questions
Are COGT insiders buying or selling?
In the last 90 days, Cogent Biosciences, Inc. (COGT) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $1.7 million by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold COGT stock?
As of June 30, 2026, the largest Cogent Biosciences, Inc. (COGT) holders among the 13F filers tracked by SignalX were FMR LLC (Fidelity) ($993.9 million), BlackRock ($671.5 million), Vanguard Portfolio Management LLC ($312.4 million), Vanguard Capital Management LLC ($286.9 million), State Street Corp ($269.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What are the main risks in COGT's latest 10-K?
In the 10-K filed February 17, 2026, Cogent Biosciences, Inc. (COGT) flagged: Regulatory risk: FDA NDA submissions for bezuclastinib in NonAdvSM (2025) and GIST (expected April 2026) may face approval delays or rejections. Macroeconomic threat: U.S. healthcare pricing pressure from May 2025 White House Most Favored Nation drug pricing policy impacting reimbursement. (AI summary of the Risk Factors section.)
What did COGT report in its latest 8-K?
Cogent Biosciences, Inc. (COGT) filed an 8-K on September 2, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Five-year supply agreement with Hovione for bezuclastinib spray-dried dispersion and tablets.
What are the latest COGT SEC filings?
Cogent Biosciences, Inc. (COGT) filed its latest 10-K annual report on February 17, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on September 2, 2026 and a Form 4 insider filing on October 5, 2026.
What is COGT's SEC CIK number?
Cogent Biosciences, Inc. (COGT)'s SEC Central Index Key (CIK) is 1622229. EDGAR lists every COGT filing under that number.
Ask anything about COGT
The research agent reads COGT's filings, financials, insider trades and 13F holders, then answers with sources.